Medicenna Therapeutics Corp (MDNA : TSX)
Common Stock
Follow MDNA
MDNA
Medicenna Therapeutics Corp
Performance
1 Day
-5.19%
1 Week
-18.89%
1 Month
-18.89%
YTD
-63.50%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$36.46M
52W High
$1.78
52W Low
$0.34
P/E Ratio
-
50 Day MA
$0.43
200 Day MA
$0.54
Beta
2.21
Dividend Yield
-
Performance history
MDNA returns since 2023
Medicenna Therapeutics Corp has traded since Nov 2023 in our data, with 1 up year out of 2 full calendar years. Its deepest fall was −87.9% (May 2024 to Jul 2026).
1 year / yr
−75.0%
3 years / yr
−10.0%
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2023*−23.6%
- 2024+292.9%
- 2025−44.2%
- 2026*−60.3%
* Partial year (first year of data, or year to date).
$10,000 invested in MDNA
- 1 year ago$2,500
- 2023 (start of our data)$6,636
- Best year
- 2024: +292.9%
- Worst year
- 2025: −44.2%
- All-time high in our data
- $3 on May 31, 2024 · now −87.2%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Nov 2026. Past returns do not predict future ones.
Earnings
MDNA earnings history
Medicenna Therapeutics Corp beat the EPS estimate in 3 of its last 4 reported quarters.
| Quarter ending | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 30, 2026 | Aug 13, 2026 | −$0.06 | −$0.06 | +0.0% |
| Mar 31, 2026 | Jun 25, 2026 | −$0.05 | −$0.06 | +16.7% |
| Dec 31, 2025 | Feb 12, 2026 | −$0.05 | −$0.06 | +16.7% |
| Sep 30, 2025 | Nov 12, 2025 | −$0.06 | −$0.07 | +14.3% |
| Jun 30, 2025 | Jul 29, 2025 | −$0.06 | −$0.05 | −20.0% |
| Mar 31, 2025 | Jun 25, 2025 | $0.02 | −$0.05 | +140.0% |
| Dec 31, 2024 | Feb 12, 2025 | −$0.07 | −$0.07 | +0.0% |
| Sep 30, 2024 | Nov 14, 2024 | −$0.05 | −$0.06 | +16.7% |
EPS as reported vs consensus estimate. TSX earnings calendar →
Awesome Portfolio™
Looking past MDNA? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/16/2026 | $0.41 | $0.41 | $0.36 | $0.36 | $0.36 | 17,853 |
| 11/13/2026 | $0.43 | $0.43 | $0.36 | $0.39 | $0.39 | 66,955 |
| 11/12/2026 | $0.41 | $0.41 | $0.39 | $0.39 | $0.39 | 35,284 |
| 11/11/2026 | $0.41 | $0.41 | $0.41 | $0.41 | $0.41 | 994 |
| 11/10/2026 | $0.45 | $0.46 | $0.40 | $0.40 | $0.40 | 187,895 |
| 11/9/2026 | $0.45 | $0.45 | $0.44 | $0.45 | $0.45 | 41,296 |
| 11/6/2026 | $0.45 | $0.45 | $0.43 | $0.44 | $0.44 | 11,564 |
| 11/5/2026 | $0.45 | $0.45 | $0.40 | $0.40 | $0.40 | 52,579 |
| 11/4/2026 | $0.45 | $0.45 | $0.42 | $0.43 | $0.43 | 11,126 |
| 11/3/2026 | $0.41 | $0.45 | $0.41 | $0.41 | $0.41 | 15,482 |
Analyst Price Targets
Based on analyst covering MDNA · as of Nov 11, 2026
Wall Street analysts forecast MDNA stock price to rise 667.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.80
+667.1% Upside
Previously C$3.20 on Sep 17, 2026
Current Price
C$0.36
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
85.5%
Annualized
90-Day Vol
64.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.26 – C$0.46 |
| 60 trading days | C$0.32 | C$0.21 – C$0.49 |
| 90 trading days | C$0.31 | C$0.18 – C$0.51 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-22.36M
- Profit Margin
- 0.00%
- ROE (TTM)
- -227.57%
- EPS (Diluted)
- -0.22
- Book Value
- 0.02
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About MDNA
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| HWO | High Arctic Energy Services Inc. | $1.74 | +29.85% |
| AAV | Advantage Oil & Gas Ltd. | $13.45 | +23.74% |
| LUC | Lucara Diamond Corp | $0.13 | +13.64% |
| T | Telus Corp | $13.70 | +12.85% |
| FRX | Fennec Pharmaceuticals Inc | $18.35 | +10.81% |
| KEL | Kelt Exploration Ltd. | $12.72 | +10.70% |
| NVO | Novo Resources Corp | $0.07 | +8.33% |
| ELO | Eloro Resources Ltd. | $1.23 | +7.89% |
Free with a Wealth Awesome account
Keep analysing MDNA, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.